A
AlphaTau
Alpha Tau Medical focuses on research, development and commercialization of Alpha DaRT for the treatment of solid cancer tumors
About AlphaTau
Alpha Tau Medical Ltd. is a pioneering medical technology company specializing in the development of advanced cancer treatments. The company focuses on patients with localized and unresectable tumors, particularly those who have limited alternative treatment options. Alpha Tau operates in the oncology market, targeting tumor types with high unmet needs such as pancreatic adenocarcinoma, glioblastoma, skin cancer, oral cavity cancer, and breast cancer. The core product, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), delivers localized radiation to destroy solid tumors while sparing surrounding healthy tissue. This innovative approach minimizes radioactive exposure and has shown promising results in combination with immunotherapies and other systemic treatments. Alpha Tau generates revenue through clinical trials and partnerships with leading cancer research institutions. The business model is centered on developing and commercializing its proprietary technology to address significant gaps in current cancer treatment options.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Jerusalem, Israel
- Employees
- 114
- Open positions
- 14
- Dealroom signal
- 49.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Oncology, Radiology, Spinout, Biotech and Pharma, DT and LS
- Technology
- Deep Tech
- Business model
- Manufacturing, SaaS
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Apr 2025 | $37M | — | Oramed | ↗ |
| IPO✓Exit | Mar 2022 | $90M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin | Profit | Margin | R&D |
|---|---|---|---|---|---|---|---|
| 2026 | — | ||||||
| 2025 | — | — | — | ||||
| 2024 | — | — | — | ||||
| 2023 | — | — | — | ||||
| 2022 | — | — | — | ||||
| 2021 | — | — | — | — | |||
| 2020 | — | — | — | — |
Growth signals
Latest recorded traffic for AlphaTau is 15K monthly website visits, up 92.3% over the last three months. AlphaTau's team grew 5.6% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
OurCrowd
Shavit Capital- MVMedison Ventures
Series B and later7 investors entered at this stage
Alan Patricof
Yozma Group
Madison Group- RVRegah Ventures
Sir Ronald Cohen
Healthcare Capital Corp
Oramed
Other known investors9 additional known investors
- DCDas & Co.
Tel Aviv University
Arc Ventures
Deep Insight- FRFederico Raccah
Medison Pharma
MUUS- RCRonald Cohen
Wyndham Wealth
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AlphaTau on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AlphaTau’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.